NCT03117946 Modulation of Anti-tumor T Cell Responses in Cancer Patients Treated by Concomitant Radiochemotherapy
| NCT ID | NCT03117946 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Besancon |
| Condition | Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 220 participants |
| Start Date | 2017-05-29 |
| Primary Completion | 2026-08-29 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 220 participants in total. It began in 2017-05-29 with a primary completion date of 2026-08-29.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to evaluate modulation of anti-tumor T cell responses in cancer patients treated by concomitant radiochemotherapy (i-RTCT)
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed NSCLC (Non Small Cell Lung Cancer) or SCLC (small cell lung cancer) OR histologically confirmed Head and neck cancer * Patient candidate to a first-line concomitant radiochemotherapy * Written informed consent Exclusion Criteria: * Sequential radiochemotherapy, exclusive radiotherapy, or stereotactic radiotherapy * History of adjuvant radiochemotherapy for cancer treatment * Patients under immunotherapy, chemotherapy or other immunosuppressive drugs (prednisone or prednisolone ≤ 10 mg/day is allowed) * HIV, hepatitis C or B virus * Patients with any medical or psychiatric condition or disease, * Patients under guardianship, curatorship or under the protection of justice.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03117946 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03117946 currently recruiting?
Yes, NCT03117946 is actively recruiting participants. Contact the research team at olivier.adotevi@univ-fcomte.fr for enrollment information.
Where is the NCT03117946 trial being conducted?
This trial is being conducted at Besançon, France, Dijon, France, Montbéliard, France, Reims, France.
Who is sponsoring the NCT03117946 clinical trial?
NCT03117946 is sponsored by Centre Hospitalier Universitaire de Besancon. The trial plans to enroll 220 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.